Hypertension affects more than 1 billion adults worldwide andis the leading cause of preventable death. Despite the plethoraof drugs available, the disease is adequately controlled inonly about one third of patients. Hormones and vasoactive peptides,like lead actors in a drama, have garnered much attention inthe context of the pathogenesis of hypertension. A recent studyby Zacchigna et al.1 has now brought to center stage a multifunctionalcytokine, transforming growth factor (TGF-).
TGF- is a ubiquitously expressed member of a superfamily ofproteins critical to developmental processes. It regulates cellgrowth and differentiation, inflammation, and . . . [Full Text of this Article]
Source Information
From Weill Medical College of Cornell University, New York (P.A., M.S.), and the Theresa and Eugene Lang Center for Research and Education, New York Hospital Queens, Flushing (P.A.).
This article has been cited by other articles:
Panoulas, V. F., Douglas, K. M. J., Smith, J. P., Stavropoulos-Kalinoglou, A., Metsios, G. S., Nightingale, P., Kitas, G. D.
(2008). Transforming growth factor-{beta}1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford)
0: ken443v1-ken443
[Abstract][Full Text]
Humphrey, J. D.
(2008). Mechanisms of Arterial Remodeling in Hypertension: Coupled Roles of Wall Shear and Intramural Stress. Hypertension
52: 195-200
[Full Text]
Feihl, F., Liaudet, L., Levy, B. I., Waeber, B.
(2008). Hypertension and microvascular remodelling. Cardiovasc Res
78: 274-285
[Abstract][Full Text]
Tong, X.-K., Hamel, E.
(2007). Transforming Growth Factor-beta1 Impairs Endothelin-1-Mediated Contraction of Brain Vessels by Inducing Mitogen-Activated Protein (MAP) Kinase Phosphatase-1 and Inhibiting p38 MAP Kinase. Mol. Pharmacol.
72: 1476-1483
[Abstract][Full Text]